Cubist Pharmaceuticals, Inc. Announces Publication Of Pivotal Data From SIVEXTRO (tedizolid phosphate) ESTABLISH-2 Clinical Trial In The Lancet Infectious Diseases
Published: Jun 06, 2014
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI). The results will also appear in a forthcoming print issue of the journal. The authors note that ESTABLISH-2 was the first prospectively designed clinical trial consistent with the fundamental elements outlined in the final U.S. Food and Drug Administration (FDA) ABSSSI Guidance released in 2013.
Help employers find you! Check out all the jobs and post your resume.